Fas expression by tumor stroma is required for cancer eradication

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2013-01-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1218295110PMID 23341634PMCID PMC3568383
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth

  2012cited by this paper
• Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis

  2011cited by this paper
• Increased Cell Surface Fas Expression Is Necessary and Sufficient To Sensitize Lung Fibroblasts to Fas Ligation-Induced Apoptosis: Implications for Fibroblast Accumulation in Idiopathic Pulmonary Fibrosis

  2011cited by this paper
• CD95 promotes tumour growth

  2011cited by this paper
• Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.

  2011cited by this paper
• Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.

  2011cited by this paper
• CD95/Fas promotes tumour growth

  2010cited by this paper
• Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.

  2009cited by this paper
• IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

  2008influential reference
• Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity.

  2007cited by this paper
• Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.

  2007cited by this paper
• IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor.

  2006cited by this paper
• Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

  2006cited by this paper
• Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.

  2006cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005influential reference
• Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance

  2005influential reference
• Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells.

  2005cited by this paper
• Effector Cell-Derived Lymphotoxin α and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases

  2004cited by this paper
• A cancer immunosurveillance controversy

  2004cited by this paper
• Bystander elimination of antigen loss variants in established tumors

  2004influential reference
• Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

  2004cited by this paper
• A Critical Requirement of Interferon γ-mediated Angiostasis for Tumor Rejection by CD8+ T Cells

  2003cited by this paper
• In Vivo Ligation of CD40 Enhances Priming Against the Endogenous Tumor Antigen and Promotes CD8+ T Cell Effector Function in SV40 T Antigen Transgenic Mice1

  2003cited by this paper
• A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.

  2003cited by this paper
• Cutting Edge: CD8+ Effector T Cells Reject Tumors by Direct Antigen Recognition but Indirect Action on Host Cells1

  2003cited by this paper
• CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications.

  2002cited by this paper
• Addiction to Oncogenes--the Achilles Heal of Cancer

  2002cited by this paper
• IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

  2001cited by this paper
• CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

  2000cited by this paper
• Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

  1996cited by this paper
• CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors.

  1996cited by this paper
• Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy.

  1995cited by this paper
• Tumor antigens.

  1992cited by this paper
• Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

  1992cited by this paper
• Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes.

  1989cited by this paper
• In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones.

  1988cited by this paper
• Tumor antigens.

  1981cited by this paper
• Loss of tumor-specific and idiotype-specific immunity with age

  1981cited by this paper

• CD8+ T cell–derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells

  2025cites this paper
• The role of CD8+ T-cells in colorectal cancer immunotherapy

  2024cites this paper
• IFNγ binding to extracellular matrix prevents fatal systemic toxicity

  2023cites this paper
• IFN-γ–dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis

  2022cites this paper
• Smart combination of aluminum hydroxide and MF59 to induce strong cellular immune responses.

  2022cites this paper
• CD8+ T cell differentiation and dysfunction in cancer

  2021cites this paper
• The role of CD4 T cells in rejection of solid tumors

  2021cites this paper
• Neuroblastoma: Current advancements and future therapeutics

  2021cites this paper
• Enhancement of Neuroblastoma NK-Cell-Mediated Lysis through NF-kB p65 Subunit-Induced Expression of FAS and PVR, the Loss of Which Is Associated with Poor Patient Outcome

  2021cites this paper
• Targeting the crosstalk between canonical Wnt/β-catenin and inflammatory signaling cascades: A novel strategy for cancer prevention and therapy.

  2021cites this paper
• DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer

  2020cites this paper
• Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo

  2020cites this paper
• Cholest-4,6-Dien-3-One Promote Epithelial-To-Mesenchymal Transition (EMT) in Biliary Tree Stem/Progenitor Cell Cultures In Vitro

  2019cites this paper
• THE IMPACT OF HISTAMINE RECEPTOR 2 ANTAGONISTS ON BREAST CANCER DEVELOPMENT AND MONOCYTIC POPULATIONS

  2018cites this paper
• Effect of a C-end rule modification on antitumor activity of thymosin α1.

  2018cites this paper
• Tumour ischaemia by interferon-γ resembles physiological blood vessel regression

  2017cites this paper
• Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes

  2017cites this paper
• Evaluating frequency and quality of pathogen-specific T cells

  2016cites this paper
• Preventing tumor escape by targeting a post-proteasomal trimming independent epitope

  2016cites this paper
• Silymarin suppressed lung cancer growth in mice via inhibiting myeloid-derived suppressor cells.

  2016cites this paper
• Gene therapy as a potential tool for treating neuroblastoma—a focused review

  2016cites this paper
• T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice

  2016influential citation
• CD8 engineered cytotoxic T cells reprogram melanoma tumor environment

  2016cites this paper
• Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice.

  2015cites this paper
• Targeting cancer-specific mutations by T cell receptor gene therapy.

  2015cites this paper
• Targeting T Cells for the Immune-Modulation of Human Diseases

  2015cites this paper
• Regulation of FasL expression, and delineation of differentiation states of cytotoxic lymphocytes

  2015cites this paper
• Priming neuroblastoma for cisplatin and etoposide drug therapy

  2015cites this paper
• Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells.

  2015cites this paper
• Cytotoxic T-cell Cytokines Put Cancer Under Arrest

  2014cites this paper
• DICE: A novel tumor surveillance mechanism-a new therapy for cancer?

  2014cites this paper
• The complex and central role of interferon‐γ in graft‐versus‐host disease and graft‐versus‐tumor activity

  2014cites this paper
• DICE

  2014cites this paper
• Expression of sphingomyelin synthase 1 (SGMS1) gene varies in human lung and esophagus cancer

  2014cites this paper
• Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

  2014cites this paper
• Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.

  2014cites this paper
• Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer

  2013cites this paper
• Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

  2013influential citation
• TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu

  2013cites this paper
• Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

  2013cites this paper